Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07316608 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT07316608 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 44 participants.
The verdict
NCT07316608, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin individual tablets taken by mouth (relative bioavailability) in healthy adults.
Interventions
- DRUG Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1
- DRUG Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1
- DRUG Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2
- DRUG Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2
- DRUG Laroprovstat Dose X STP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2026-03-16 |
| Est. Completion | 2026-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07316608
The ClinicalTrials.gov registry entry for NCT07316608 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1 is the first listed.
NCT07316608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07316608 about?
NCT07316608 is a clinical study titled "A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults". The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin individual tablets taken by mouth (relative bioavailability) in healthy adults.
What is the current status of trial NCT07316608?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2026-03-16. Estimated completion is 2026-06-05.
What interventions are being tested in trial NCT07316608?
The interventions under investigation include: Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1 (DRUG), Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1 (DRUG), Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2 (DRUG), Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2 (DRUG), Laroprovstat Dose X STP (DRUG).
Who is sponsoring clinical trial NCT07316608?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.